solver.press

Evolutionary trade-offs observed in antibiotic resistance can be mathematically modeled using complex interpolation of matrices to predict compensatory mutation pathways.

BiologyApr 22, 2026Evaluation Score: 72%

Adversarial Debate Score

53% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Grok: The hypothesis is falsifiable as it can be tested through mathematical modeling and experimental validation of predicted mutation pathways; however, the provided papers focus on empirical observations of trade-offs rather than mathematical modeling, leaving the specific approach of complex matrix...
Mistral: The hypothesis is falsifiable and aligns with existing literature on evolutionary trade-offs, but its reliance on "complex interpolation of matrices" is vague and lacks direct empirical support in the provided papers, leaving room for counterarguments about model feasibility.
ChatGPT: The hypothesis is falsifiable and conceptually intriguing, but the cited papers establish evolutionary trade-offs and compensatory mutations without supporting the specific mathematical framework of "complex interpolation of matrices" for modeling or prediction; thus, the leap to this mathematica...
Claude: The hypothesis is weakly supported because while the cited papers clearly document evolutionary trade-offs and compensatory mutations in antibiotic resistance, none of them employ or validate matrix interpolation as a predictive mathematical framework; the specific claim about "complex interpolat...

Supporting Research Papers

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

In a defined, contained Escherichia coli K-12 experimental-evolution system, compensatory evolution after acquisition of antibiotic resistance can be represented as transitions among genotype–phenotype states, and a complex-spectral interpolation model of environment-specific transition matrices will predict the next compensatory gene or pathway in previously unseen lineages more accurately than empirical-frequency, fitness-only, real-valued linear-interpolation, generalized linear, and sequence-based machine-learning baselines.

The primary falsifiable comparison is prospective pathway-level prediction. Before each new evolutionary interval is observed, the model must assign probabilities to the compensatory pathway that subsequently emerges. The prespecified effect is:

  • At least 0.60 top-5 recall for the next validated compensatory pathway.
  • At least a 20% reduction in multiclass log loss relative to the best prespecified baseline.
  • At least a 10% reduction in log loss relative to a parameter-matched real-valued interpolation ablation.
  • Calibration error no greater than 0.10.
  • Reproduction of the effect in at least two antibiotic classes and at least three independent primary-resistance backgrounds per class.

A “compensatory mutation” is defined operationally as a secondary mutation or mutation module that, relative to its immediate resistant ancestor:

  1. Increases antibiotic-free growth rate or competitive fitness by at least 10%;
  2. Retains at least 80% of the ancestor’s resistance phenotype, measured on the same standardized susceptibility scale; and
  3. Is supported causally by reconstruction in a nonpathogenic background, reversion, or an equivalently strong isogenic comparison.

The matrix claim is not satisfied merely by fitting retrospective observations. Predictions must be generated from a frozen model before the corresponding held-out lineage interval or prospective experiment is decoded.

Disproof criteria:

The central hypothesis is disproved for the tested domain if any of the following occurs in a preregistered, leakage-controlled evaluation:

  1. The complex-spectral model fails to outperform the best prespecified baseline on prospective multiclass log loss, with the 95% confidence interval for relative improvement including zero or favoring the baseline.

  2. The parameter-matched complex model does not outperform the real-valued interpolation ablation by at least 10% in relative log loss, or its 95% bootstrap confidence interval includes zero improvement.

  3. Top-5 pathway recall is below 0.45 in the prospective test set or below 0.50 in two or more antibiotic classes.

  4. Performance disappears under founder-grouped validation, indicating that the original result came from leakage among descendants of the same resistant ancestor.

  5. Performance disappears when evaluation is restricted to mutations observed after the prediction freeze date.

  6. Predicted “compensatory” mutations restore neither fitness nor growth cost under an isogenic comparison, or they restore fitness only by substantially eliminating resistance.

  7. The model’s apparent advantage is reproduced by a label-frequency model after controlling for pathway prevalence, indicating that it predicts common pathways rather than context-specific transitions.

  8. Complex eigenmodes or matrix-logarithm branches are unstable across bootstrap samples: for example, fewer than 70% of resamples retain aligned spectral modes or model predictions change by more than 0.20 mean total-variation distance under small numerical perturbations.

  9. Leave-one-antibiotic-class-out testing yields performance at or below a frequency baseline, refuting the broader transfer claim even if within-class interpolation remains useful.

  10. Independent reanalysis by a second analyst cannot reproduce the primary result from the frozen data, container, seed list, and model configuration.

A negative result would not disprove the general existence of evolutionary trade-offs. It would specifically disprove the claim that the proposed complex matrix interpolation provides reliable predictive value under the tested conditions.

Spine & Adversarial ReadReady for validation

“Complex spectral interpolation of environment-specific evolutionary transition matrices predicts compensatory antibiotic-resistance pathways more accurately than real-valued and non-matrix baselines.”

  • highComplex-valued matrix interpolation has no established biological interpretation, and any improvement may result from additional flexibility, branch selection, or stochastic-matrix projection rather than a real evolutionary mechanism.
    The EVP compares the model with parameter-matched real interpolation, penalizes unstable branches, measures projection distance, tests synthetic systems with and without complex modes, and requires a prospective advantage after ablation of complex phase information. Even if prediction improves, mechanistic interpretation will remain limited unless stable spectral modes map reproducibly to measurable ecological or genetic cycles.
  • highThe selected organism, datasets, and state representation may be chosen for convenience rather than because they are the correct methodology for antimicrobial-resistance evolution.
    E. coli K-12 is selected for containment, annotation quality, tractable replication, and compatibility with EcoCyc, CARD, SRA, and ENA data; pathway-level states are selected because exact nucleotide transitions are too sparse for an adequately powered first test. The design nevertheless requires gene-level sensitivity analyses, founder-grouped validation, three antibiotic classes, and leave-class-out testing. It does not resolve transfer to clinical pathogens, horizontal gene transfer, host environments, or combination therapy, which require follow-on EVPs.
  • highEvolutionary trajectories may be fundamentally history-dependent and underdetermined, so recurrent pathway prediction could collapse outside closely related founders even if retrospective within-system accuracy is high.
    Founder-grouped prospective testing, leave-one-environment-out testing, leave-one-class-out testing, no-event modeling, and comparison with simple pathway-frequency priors directly test this objection. Failure under founder grouping disproves the transferable version of the claim; success only within founders would narrow the result to local interpolation rather than general evolutionary forecasting.

Experimental Protocol

The minimum viable experiment combines retrospective model development with a prospectively frozen experimental-evolution test.

A. Biological system

  • Organism: a nonpathogenic E. coli K-12 reference background.
  • Antibiotic coverage: three mechanistically distinct antibiotic classes selected after institutional biosafety review and baseline susceptibility testing.
  • Primary-resistance backgrounds: four independently derived or archived resistant founders per antibiotic class, for 12 founders total.
  • Exposure environments:
    1. Constant low selective pressure;
    2. Constant moderate selective pressure;
    3. Predefined fluctuating pressure.
  • Replication: five independent lineages per founder–environment combination.
  • Prospective evolving lineages: 12 founders × 3 environments × 5 replicates = 180 lineages.
  • Controls:
    • 15 no-antibiotic control lineages;
    • 15 resistant-founder controls maintained without antibiotic;
    • Frozen immediate-ancestor samples for every sequenced interval;
    • Technical sequencing duplicates for 10% of samples;
    • Blinded phenotype repeats for 10% of isolates.

Exact culture and handling parameters should be established by the approved institutional SOP rather than optimized for maximal resistance. The design requires consistent transfer intervals and approximately 30–50 temporally ordered observations per lineage where feasible.

B. Sampling

  • Measure bulk growth at every transfer or observation interval.
  • Archive populations at least every fifth transfer interval.
  • Sequence population samples at approximately 8–10 time points per lineage.
  • Isolate and sequence representative clones at the resistant-founder stage, at candidate compensatory sweeps, and at the endpoint.
  • Measure susceptibility and drug-free growth for all founders, endpoints, and candidate transition isolates.
  • Use long-read sequencing on all founders and at least one endpoint per founder–environment combination to resolve structural variants.

Expected minimum sequencing volume:

  • 180 lineages × 9 population time points = 1,620 population genomes;
  • Approximately 300 clonal genomes;
  • Approximately 50 long-read genomes;
  • Total: approximately 1,970 sequencing libraries.

C. Retrospective training data

Before prospective decoding, construct a training corpus from:

  • Qualifying serial-evolution datasets in NCBI Sequence Read Archive and European Nucleotide Archive;
  • Publicly deposited E. coli resistance-evolution experiments with ordered samples and recorded antibiotic environments;
  • Internal pilot lineages, if available, kept strictly separate from the prospective test;
  • Resistance annotation from CARD and MEGARes;
  • Gene and pathway annotation from EcoCyc, UniProt, Gene Ontology, and BV-BRC.

Only datasets containing an identifiable ancestor, at least three ordered time points, phenotype or exposure metadata, and sufficient sequencing depth are eligible.

D. Prediction freeze

After the prospective experiment is started but before later samples are sequenced:

  1. Freeze the genotype-state vocabulary and pathway mapping.
  2. Freeze matrix-estimation rules and hyperparameters.
  3. Train the model only on retrospective data and already decoded pilot intervals.
  4. Hash and timestamp the model container, configuration, pathway dictionary, and prediction files.
  5. Generate ranked pathway probabilities for each blinded lineage interval.
  6. Decode subsequent samples only after predictions are locked.

E. Primary analysis unit

The primary unit is one eligible ancestor-to-descendant interval. Intervals descending from the same founder remain in the same split. The outcome is the first compensatory pathway crossing a prespecified detection threshold. Intervals with no compensatory event are retained as a “none detected” class or handled by a competing-risk survival formulation.

F. Causal validation

Select:

  • The ten highest-confidence predicted pathways that subsequently occur;
  • Five high-confidence predictions that do not occur;
  • Five unpredicted recurrent pathways.

Test these in matched, nonpathogenic resistant backgrounds using institutionally approved isogenic reconstruction, reversion, or equivalent causal comparison. Each comparison should include at least three independent biological replicates and blinded phenotype measurement.

Required datasets:
  1. Prospective lineage dataset

    • Approximately 180 minimum-test lineages or 360 full-test lineages.
    • Founder identifier, antibiotic class, environment, time point, replicate, growth phenotype, susceptibility phenotype, sequencing batch, and population allele frequencies.
    • Immediate ancestry links between adjacent observations.
    • Expected storage: 12–20 TB of raw and processed short-read data for the minimum test; 30–45 TB for the full study.
  2. NCBI Sequence Read Archive

    • Candidate retrospective time-series datasets for bacterial experimental evolution.
    • Inclusion requires ordered samples, ancestor information, antibiotic metadata, and reusable raw reads.
    • Every included BioProject and accession must be listed in the preregistration and final data manifest.
  3. European Nucleotide Archive

    • Used to locate additional serial-evolution datasets and mirrors of qualifying SRA records.
    • Duplicate records must be deduplicated by accession and sample checksum.
  4. CARD

    • Used to annotate known antibiotic-resistance genes and resistance-associated variants.
    • Database version and retrieval date must be frozen.
  5. MEGARes

    • Secondary resistance ontology and annotation source.
    • Disagreements with CARD must be retained as provenance rather than silently resolved.
  6. EcoCyc

    • Source for E. coli operons, regulatory relationships, metabolic pathways, and functional modules.
    • Primary pathway-level state aggregation should be based on a frozen EcoCyc release.
  7. UniProt and Gene Ontology

    • Protein-function and ontology features for transfer among genes with similar biological roles.
    • Ontology propagation must be limited to documented parent relationships to prevent overly broad labels.
  8. BV-BRC

    • Comparative bacterial genome context and strain metadata.
    • Used only for annotation and external contextualization in the minimum experiment, not as a source of unlabeled clinical outcomes.
  9. Reference genome and annotations

    • A single frozen E. coli K-12 reference assembly and annotation.
    • All variants must be normalized to this reference, with structural variants represented separately.
  10. Phenotype dataset

    • Drug-free maximum growth rate, lag time, carrying-capacity proxy, competitive fitness where available, and standardized susceptibility measurements.
    • Minimum technical coefficient of variation target: below 10% for growth and below one dilution step for susceptibility.
  11. Environmental metadata

    • Encoded drug class, normalized exposure relative to the lineage’s measured susceptibility, resource condition, temperature, transfer interval, and whether exposure is constant or fluctuating.
  12. Negative-control datasets

    • No-drug evolution lineages.
    • Label-permuted transition datasets.
    • Simulated Markov systems with known transition operators.
    • Simulated systems with no complex modes, used to determine whether the method spuriously creates a complex-model advantage.
Success:

The EVP is successful only if all primary criteria and at least four of the six secondary criteria are met.

Primary criteria

  1. Prospective top-5 compensatory-pathway recall is at least 0.60, with a 95% confidence-interval lower bound above 0.45.

  2. Prospective multiclass log loss is at least 20% lower than the best prespecified non-complex baseline, with the 95% paired-bootstrap lower bound showing at least 5% improvement.

  3. The complex-spectral model achieves at least 10% lower log loss than its parameter-matched real-valued interpolation ablation, with the 95% confidence interval excluding zero improvement.

  4. Expected calibration error is no greater than 0.10 and calibration slope lies between 0.8 and 1.2.

  5. The result holds in at least two of three antibiotic classes and at least three independent resistance backgrounds per successful class.

  6. At least 6 of 10 selected correctly predicted pathways meet the causal compensatory definition in an isogenic, reversion, or equivalent controlled comparison.

Secondary criteria

  1. Mean reciprocal rank is at least 0.45.
  2. Top-1 accuracy is at least 0.25.
  3. Brier score improves by at least 10% relative to the best baseline.
  4. Leave-one-environment-out log loss improves by at least 10%.
  5. Leave-one-antibiotic-class-out top-5 recall is at least 0.40.
  6. At least 70% of aligned complex spectral modes recur across founder-clustered bootstrap samples.

The intervention-strategy claim is considered only provisionally supported if predicted environment changes reduce the incidence of a targeted compensatory pathway by at least 30% in at least two preregistered tests without increasing the frequency of another resistance pathway by more than 20%.

Failure:
  1. Fewer than 100 eligible prospective transition intervals remain after quality control.
  2. Fewer than three independent primary-resistance backgrounds are available for two or more antibiotic classes.
  3. More than 25% of prospective intervals have unresolved mutation order.
  4. Sequencing or phenotype batches are confounded with environment or founder.
  5. The complex model’s primary advantage is below 5% relative log-loss improvement.
  6. A frequency-only baseline matches or exceeds the complex model.
  7. Founder-grouped performance is materially lower than random-split performance and no longer exceeds baseline.
  8. Calibration error exceeds 0.15 after training-only calibration.
  9. Fewer than 50% of predicted compensatory pathways restore fitness in controlled validation.
  10. Resistance retention fails in more than half of candidate compensatory events.
  11. Numerical projection changes interpolated matrices by more than 0.05 normalized Frobenius distance in over 10% of predictions.
  12. Model rankings change by more than 0.20 mean total-variation distance across reasonable matrix-logarithm branches.
  13. Results cannot be reproduced by the independent analyst.
  14. A biosafety, contamination, strain-identity, or containment deviation compromises lineage independence or experimental validity.

800

GPU hours

180d

Time to result

$85,000

Min cost

$420,000

Full cost

ROI Projection

Commercial:
  1. Antibiotic development: A forecasting platform could rank likely compensatory routes during lead optimization, helping sponsors compare compounds that have similar immediate activity but different long-term resistance liabilities.

  2. Combination and sequencing research: The model could prioritize treatment sequences or companion compounds predicted to block high-probability compensation pathways. Such recommendations would require separate safety and efficacy validation.

  3. Diagnostic decision support: After clinical validation, genotype and susceptibility data could feed a probabilistic report of likely next resistance or compensation pathways. The present EVP supports only the underlying forecasting method, not patient-level use.

  4. Surveillance: Public-health laboratories could use pathway probabilities to prioritize which emerging variants require phenotypic confirmation.

  5. Licensing model: Potential products include research software licenses, analysis services, resistance-risk reports, or integration into antimicrobial-development platforms.

  6. Commercial milestones:

    • Research-use-only prototype after successful full validation: 9–15 months.
    • Multispecies preclinical platform: 24–36 months.
    • Clinically evaluated decision-support system: at least 4–6 years.
  7. Indicative value: A validated research platform could plausibly support annual contracts of $100,000–$500,000 per pharmaceutical customer or project-based studies costing $150,000–$750,000. These figures are market-oriented estimates, not guaranteed revenue.

Implementation Sketch

SYSTEM NAME
    COMPASS-AMR:
    Complex Operator Modeling for Prediction of Antibiotic
    Secondary and Suppressor trajectories

HIGH-LEVEL COMPONENTS
    1. Immutable data registry
    2. Sequencing and phenotype ingestion
    3. Variant-trajectory engine
    4. Gene/pathway ontology mapper
    5. Transition-state constructor
    6. Complex spectral interpolation model
    7. Baseline-model suite
    8. Prospective prediction freezer
    9. Evaluation and statistical inference
   10. Wet-laboratory validation tracker
   11. Reproducibility and audit layer


A. PROJECT SETUP

function initialize_project(config):
    assert config.reference_genome_version is fixed
    assert config.CARD_version is fixed
    assert config.EcoCyc_version is fixed
    assert config.primary_metric == "prospective_multiclass_log_loss"
    assert config.split_unit == "resistant_founder"
    assert config.bootstrap_replicates >= 2000

    create_read_only_directory("/registry/raw")
    create_versioned_directory("/registry/processed")
    create_versioned_directory("/models")
    create_append_only_directory("/predictions_frozen")
    create_append_only_directory("/audit")

    write_preregistration_hash(config)
    build_containers([
        "read_qc",
        "variant_calling",
        "structural_variant_calling",
        "phenotype_processing",
        "matrix_model",
        "baseline_models",
        "evaluation"
    ])

    validate_biosafety_approval(config.strain_ids)
    validate_no_clinical_enhancement_work(config.protocol)


B. DATA MODEL

SampleRecord:
    sample_id
    lineage_id
    founder_id
    parent_sample_id
    antibiotic_class
    environment_id
    observation_index
    collection_timestamp
    sequencing_batch
    phenotype_batch
    blinded_status
    raw_read_uris
    checksums

PhenotypeRecord:
    sample_id
    drug_free_growth_rate
    lag_time
    carrying_capacity_proxy
    susceptibility_measure
    replicate_count
    measurement_uncertainty

VariantRecord:
    sample_id
    chromosome_or_contig
    normalized_position
    reference_allele
    alternate_allele
    variant_type
    allele_frequency_mean
    allele_frequency_interval
    read_depth
    quality_flags

TransitionRecord:
    lineage_id
    founder_id
    source_observation
    target_observation
    source_state
    target_state
    candidate_event_set
    environmental_vector
    compensation_label
    interval_censored
    observation_weight


C. INGESTION AND QUALITY CONTROL

function ingest_sample(sample_manifest):
    for sample in sample_manifest:
        verify_checksum(sample.raw_reads)
        verify_sample_id_unique(sample.sample_id)
        verify_parent_link(sample.parent_sample_id)
        register_sample(sample)

function run_sequence_pipeline(sample):
    qc = quality_control_reads(sample.raw_reads)

    if qc.contamination_score > CONFIG.max_contamination:
        quarantine(sample, reason="possible contamination")
        return

    aligned_reads = map_to_frozen_reference(
        qc.cleaned_reads,
        reference=CONFIG.reference_genome
    )

    small_variants = call_small_variants(aligned_reads)
    copy_number = estimate_copy_number(aligned_reads)
    structural_variants = call_structural_variants(aligned_reads)

    normalized = normalize_variants(
        small_variants,
        copy_number,
        structural_variants
    )

    save_with_provenance(normalized)

function process_phenotypes(raw_phenotype_table):
    randomization_check(raw_phenotype_table)
    estimate_plate_and_batch_effects()
    calculate_growth_parameters()
    calculate_susceptibility_with_uncertainty()

    if technical_CV > 0.10:
        flag_batch_for_repeat()

    return standardized_phenotypes


D. TRAJECTORY INFERENCE

function infer_lineage_trajectory(lineage_samples):
    sort lineage_samples by observation_index

    for variant in union_of_variants(lineage_samples):
        posterior_trajectory = estimate_frequency_posterior(
            variant_counts_over_time,
            read_depth_over_time,
            sequencing_error_model
        )

        establishment_interval = first_interval_where(
            posterior_probability(
                frequency > CONFIG.establishment_threshold
            ) >= CONFIG.posterior_threshold
        )

        if multiple_events_share_unresolved_interval:
            emit_set_valued_event(
                variants=events,
                interval_censored=True
            )
        else:
            emit_ordered_event(variant, establishment_interval)

    return ancestry_consistent_event_graph


E. PATHWAY AND STATE CONSTRUCTION

function map_variant_to_modules(variant):
    gene = annotate_against_reference(variant)
    resistance_labels = query_CARD_and_MEGARes(gene, variant)
    ecocyc_modules = query_EcoCyc(gene)
    go_terms = query_GO(gene)
    protein_features = query_UniProt(gene)

    return ModuleMapping(
        gene=gene,
        operons=ecocyc_modules.operons,
        pathways=ecocyc_modules.pathways,
        resistance_terms=resistance_labels,
        functional_terms=go_terms,
        provenance=all_database_versions
    )

function build_state(sample, ancestor, environment):
    resistance_modules = modules_with_established_variants(sample)
    resistance_bin = discretize_resistance(sample.susceptibility)
    cost_bin = discretize(
        ancestor.drug_free_growth - sample.drug_free_growth
    )

    return State(
        active_modules=resistance_modules,
        resistance_bin=resistance_bin,
        fitness_cost_bin=cost_bin,
        environment_vector=encode_environment(environment)
    )

function classify_compensation(source, target):
    fitness_change = (
        target.drug_free_growth - source.drug_free_growth
    ) / source.drug_free_growth

    resistance_retention = (
        target.resistance_measure / source.resistance_measure
    )

    if fitness_change >= 0.10 and resistance_retention >= 0.80:
        return "candidate_compensatory"
    elif resistance_retention < 0.80:
        return "reversion_or_resensitization"
    else:
        return "noncompensatory_or_uncertain"


F. TRANSITION MATRIX ESTIMATION

function construct_transition_counts(records, state_dictionary):
    for environment e:
        C_e = zero_matrix(number_of_states)

        for record in records where record.environment == e:
            i = state_dictionary.index(record.source_state)
            j = state_dictionary.index(record.target_state)

            weight = record.observation_weight

            if record.interval_censored:
                distribute weight across candidate target states
                according to uncertainty model
            else:
                C_e[i, j] += weight

        C_e = hierarchical_dirichlet_smooth(
            C_e,
            pathway_parent_counts,
            alpha=hyperparameter_selected_inside_training_only_CV
        )

        T_e = row_normalize(C_e)
        assert approximately_row_stochastic(T_e)

        save(T_e, uncertainty=cluster_bootstrap(records))

    return environment_transition_operators


G. TRADE-OFF OPERATOR

function construct_tradeoff_matrix(records):
    for transition i -> j:
        delta_fitness = standardized_change_in_drug_free_growth
        retained_resistance = standardized_resistance_retention
        exposure_growth = standardized_growth_under_exposure

        F[i, j] = weighted_combination(
            delta_fitness,
            retained_resistance,
            exposure_growth,
            weights_learned_on_training_data_only
        )

    return F

function augment_operator(T, F):
    # Keep transition probabilities and phenotype effects distinct
    # while allowing the interpolation model to use both.
    A = block_matrix([
        [regularize(T),        CONFIG.lambda_tradeoff * F],
        [zero_matrix_like(T),  identity_matrix(size(T))]
    ])

    return A


H. COMPLEX SPECTRAL INTERPOLATION

function stable_complex_representation(A):
    # Add only the regularization selected during inner CV.
    A_reg = regularize_for_condition_number(A)

    U, S = complex_schur_decomposition(A_reg)

    eigenmodes = extract_conjugate_paired_modes(U, S)

    if condition_number(U) > CONFIG.max_condition_number:
        return failure("unstable spectral basis")

    return SpectralRepresentation(U, S, eigenmodes)

function align_modes(rep_a, rep_b):
    cost_matrix = matrix()

    for mode p in rep_a.modes:
        for mode q in rep_b.modes:
            eigenvalue_cost = abs(p.eigenvalue - q.eigenvalue)
            vector_cost = 1 - abs(inner_product(p.vector, q.vector))
            conjugacy_penalty = incompatible_pair_penalty(p, q)

            cost_matrix[p, q] = (
                w1 * eigenvalue_cost +
                w2 * vector_cost +
                w3 * conjugacy_penalty
            )

    assignment = hungarian_algorithm(cost_matrix)
    return reorder_and_phase_align(rep_b, assignment)

function choose_log_branch(representations, training_transitions):
    candidates = enumerate_prespecified_branches(
        max_phase_wrap=CONFIG.max_phase_wrap
    )

    for branch in candidates:
        score = training_negative_log_likelihood(branch)
        instability = perturbation_instability(branch)
        imaginary_residual = reconstruction_imaginary_norm(branch)

        objective[branch] = (
            score +
            CONFIG.stability_penalty * instability +
            CONFIG.imaginary_penalty * imaginary_residual
        )

    return argmin(objective)

function interpolate_operator(anchor_operators, target_environment):
    reps = [
        stable_complex_representation(A)
        for A in anchor_operators
    ]

    reps = jointly_align_all_modes(reps)
    branch = choose_log_branch(reps, training_transitions)

    weights = environment_interpolation_weights(
        anchor_environment_vectors,
        target_environment,
        method=CONFIG.environment_kernel
    )

    interpolated_log_magnitudes = weighted_sum(
        weights,
        [log_mode_magnitudes(rep, branch) for rep in reps]
    )

    interpolated_phases = weighted_sum(
        weights,
        [unwrapped_mode_phases(rep, branch) for rep in reps]
    )

    interpolated_subspaces = unitary_geodesic_interpolation(
        [rep.invariant_subspaces for rep in reps],
        weights
    )

    A_complex = reconstruct_from_modes(
        interpolated_log_magnitudes,
        interpolated_phases,
        interpolated_subspaces
    )

    A_reconstructed = matrix_exponential(A_complex)

    imaginary_residual = norm(imaginary_part(A_reconstructed))
    A_real = real_part_after_conjugate_pair_reconstruction(A_reconstructed)

    T_raw = extract_transition_block(A_real)
    T_projected = nearest_row_stochastic_matrix(T_raw)

    projection_distance = normalized_frobenius_distance(
        T_raw,
        T_projected
    )

    diagnostics = {
        "imaginary_residual": imaginary_residual,
        "projection_distance": projection_distance,
        "condition_number": maximum_condition_number(reps),
        "branch": branch
    }

    if projection_distance > CONFIG.abort_projection_distance:
        mark_prediction_unreliable()

    return T_projected, diagnostics


I. PREDICTION

function predict_next_pathway(lineage_state, target_environment, model):
    T, diagnostics = model.interpolate_operator(target_environment)

    current_index = state_dictionary.index(lineage_state)
    state_probabilities = T[current_index, :]

    pathway_probabilities = aggregate_state_probabilities_to_pathways(
        state_probabilities,
        ontology=CONFIG.frozen_pathway_ontology
    )

    no_event_probability = competing_risk_no_event_model(
        lineage_state,
        target_environment
    )

    full_distribution = normalize(
        pathway_probabilities + no_event_probability
    )

    return Prediction(
        ranked_pathways=sort_descending(full_distribution),
        diagnostics=diagnostics
    )


J. BASELINE CONTROLS

function train_all_baselines(training_data):
    models = {}

    models["global_frequency"] = fit_global_frequency(training_data)
    models["class_frequency"] = fit_class_frequency(training_data)
    models["empirical_markov"] = fit_empirical_markov(training_data)
    models["fitness_only"] = fit_multinomial_fitness_model(training_data)
    models["real_linear"] = fit_real_convex_interpolation(training_data)
    models["real_log_euclidean"] = fit_real_log_interpolation(training_data)
    models["multinomial_glm"] = fit_regularized_multinomial(training_data)
    models["boosted_trees"] = fit_grouped_gradient_boosting(training_data)

    if effective_training_events >= CONFIG.minimum_neural_sample:
        models["pathway_neural"] = fit_pathway_feature_network(
            training_data
        )

    return models


K. SPLITTING AND LEAKAGE CONTROL

function create_grouped_splits(records):
    groups = unique(records.founder_id)

    outer_splits = grouped_cross_validation(
        groups=groups,
        stratify_by=[antibiotic_class, environment]
    )

    for split in outer_splits:
        assert no_founder_overlap(split.train, split.test)
        assert no_descendant_overlap(split.train, split.test)
        assert all_hyperparameters_fit_only_on(split.train)

    return outer_splits

function prospective_freeze(predictions, config, model):
    artifact = {
        "predictions": predictions,
        "model_hash": sha256(model),
        "config_hash": sha256(config),
        "ontology_hash": sha256(CONFIG.pathway_ontology),
        "timestamp": trusted_timestamp(),
        "allowed_evaluation_code_hash": sha256(evaluation_container)
    }

    write_once("/predictions_frozen/" + artifact.timestamp, artifact)
    lock_permissions()
    return artifact


L. EVALUATION

function evaluate_predictions(frozen_predictions, decoded_outcomes):
    verify_prediction_timestamp_precedes_outcome_decoding()

    metrics = {
        "log_loss": multiclass_log_loss(),
        "brier_score": multiclass_brier_score(),
        "top1_accuracy": top_k_recall(k=1),
        "top3_recall": top_k_recall(k=3),
        "top5_recall": top_k_recall(k=5),
        "mean_reciprocal_rank": MRR(),
        "expected_calibration_error": ECE(bins=10),
        "calibration_slope": calibration_slope()
    }

    confidence_intervals = founder_clustered_bootstrap(
        metrics,
        replicates=2000
    )

    paired_differences = compare_against_each_baseline(
        metric="log_loss",
        bootstrap_clusters="founder_id"
    )

    return metrics, confidence_intervals, paired_differences


M. ABLATION AND ADVERSARIAL TESTS

function run_ablation_suite():
    configurations = [
        "full_complex_model",
        "remove_complex_phase",
        "real_only_interpolation",
        "remove_tradeoff_matrix",
        "remove_environment_covariates",
        "remove_module_pooling",
        "remove_structural_variants",
        "remove_public_training_data"
    ]

    for configuration in configurations:
        retrain_inside_identical_grouped_splits()
        evaluate_on_same_frozen_test_intervals()
        store_paired_metric_difference()

function run_negative_controls():
    for iteration in 1..500:
        permute_outcomes_within_antibiotic_class()
        train_and_evaluate_complete_pipeline()

    simulate_real_spectrum_markov_systems()
    simulate_complex_conjugate_mode_systems()
    simulate_history_dominated_unique_pathways()

    assert model_does_not_claim_complex_advantage_on_real_only_systems()
    estimate_power_to_detect_known_complex_advantage()


N. CAUSAL VALIDATION TRACKER

function select_candidates_for_validation(predictions, outcomes):
    selected = stratified_select(
        10 correctly_predicted_high_confidence,
        5 predicted_but_not_observed,
        5 recurrent_unpredicted
    )

    return selected

function register_validation_result(candidate):
    require at_least_3_biological_replicates
    require blinded_labels
    require matched_resistant_ancestor
    require randomized_measurement_positions

    fitness_restoration = estimate_mixed_effect(
        outcome="drug_free_growth",
        fixed_effect="genotype",
        random_effect="batch"
    )

    resistance_retention = calculate_retention_ratio()

    candidate.causally_validated = (
        fitness_restoration.relative_effect >= 0.10 and
        resistance_retention >= 0.80 and
        confidence_interval_supports_effect
    )


O. OUTPUTS

Final output directory contains:
    1. Frozen prediction distributions
    2. Prospective metric table and confidence intervals
    3. Baseline and ablation comparison table
    4. Calibration plots
    5. Founder-grouped and leave-class-out analyses
    6. Spectral-mode stability report
    7. Matrix projection and branch diagnostics
    8. Causal phenotype-validation report
    9. Complete inclusion/exclusion manifest
   10. Containers, environment files, and random seeds
   11. Independent reproduction report
   12. Go/no-go decision against preregistered criteria
Abort checkpoints:
  1. Day 30 — data feasibility:
    Abort or redesign if fewer than 500 qualifying retrospective transition intervals are identified, fewer than three antibiotic classes have usable metadata, or more than 40% of candidate public samples lack resolvable ancestry.

  2. Day 45 — pilot assay quality:
    Abort phenotypic expansion if technical growth-rate coefficient of variation exceeds 15%, susceptibility controls vary by more than two dilution steps, or strain-identity checks fail in more than 2% of samples.

  3. Day 60 — lineage viability and independence:
    Abort affected conditions if more than 25% of lineages are lost, contaminated, or cross-mixed, or if fewer than three independent resistant founders remain in a class.

  4. Day 75 — matrix estimability:
    Collapse state resolution or stop complex modeling if more than 80% of transition cells are unsupported and hierarchical pooling produces an effective sample size below five for most target modules.

  5. Day 90 — numerical stability:
    Abort the complex-model claim if more than 20% of fitted operators have condition number above the preregistered limit, projection distance exceeds 0.05 in over 10% of cases, or branch changes produce more than 0.20 total-variation change.

  6. Day 105 — retrospective benchmark:
    Stop prospective scale-up if grouped cross-validation shows less than 5% log-loss improvement over the best baseline or if random-split gains disappear under founder grouping.

  7. Day 135 — prospective event yield:
    Extend observation or terminate as underpowered if fewer than 100 eligible compensatory-transition intervals are available.

  8. Day 165 — frozen primary evaluation:
    Reject the hypothesis if prospective top-5 recall is below 0.45, complex-vs-real improvement is nonpositive, or calibration error exceeds 0.15.

  9. Day 210 — causal validation:
    Do not advance to intervention testing if fewer than 50% of selected predicted pathways satisfy fitness-restoration and resistance-retention criteria.

  10. Any time — safety or integrity:
    Immediately suspend work for containment failure, unapproved strain use, material sample-identity uncertainty, evidence of cross-contamination, or deviation from the prospective prediction freeze.

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started